Carmelo SCARPIGNATO

Professor of Clinical Pharmacology

University of Parma

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Carmelo Scarpignato is a faculty member in the Department of Clinical Pharmacology at the University of Parma, Italy. His research focuses on gastroesophageal reflux disease (GERD), including therapies such as potassium-competitive acid blockers and the role of medical devices in mucosal protection. He has contributed to the development of national guidelines and has published extensively on topics related to esophagitis and diverticulosis.

Articles (19)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (7)

NICOLA DE BORTOLI

Associate Professor

University of Pisa

ITALY

View details

Giuseppe Esposito

Assistant professor in pharmacology and therapeutics

ITALY

View details

Colin Howden

Professor Emeritus

UNITED STATES

View details

Yuhong Yuan

Assistant Professor (Part-time)

McMaster University

CANADA

View details

Richard Hunt

CANADA

View details

Peter Whorwell

The University of Manchester

UNITED KINGDOM

View details

Edoardo Savarino

Associate Professor

University of Padua

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Carmelo SCARPIGNATO

Research Interests

Explore related searches

Contact this professor

About

Articles (19)

Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD

From erosive to non-erosive reflux disease: broadening the scope of P-CAB therapy

Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease

Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates

Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners

Predictive Score for Advanced Colorectal Neoplasia Based on Cardiovascular and Colorectal Cancer Risk Factors

A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection

Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted Patients

Review article: rethinking the "ladder" approach to reflux-like symptom management in the era of PPI "resistance" - a multidisciplinary perspective.

A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure.

Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option?

Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

Correction to: Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine

Editorial: acid suppression with potassium‐competitive acid blockers dismissing genotype concerns

Colonic diverticular disease

Collaborators (7)

NICOLA DE BORTOLI

Giuseppe Esposito

Colin Howden

Yuhong Yuan

Richard Hunt

Peter Whorwell

Edoardo Savarino

Make your next move.